Raphael J Landovitz

Title(s)Professor, Medicine
Address760 Westwood Plaza 32-144
Los Angeles CA 90024
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Biomedical Prevention for HIV in High-risk Populations with Comorbidities
    NIH K23DA026308Sep 1, 2009 - Jun 30, 2014
    Role: Principal Investigator
    UCLA AIDS Prevention and Treatment Clinical Trials Unit
    NIH UM1AI069424Feb 1, 2007 - Nov 30, 2027
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study. ACS Pharmacol Transl Sci. 2021 Feb 12; 4(1):226-239. Seneviratne HK, Hamlin AN, Li S, Grinsztejn B, Dawood H, Liu AY, Kuo I, Hosseinipour MC, Panchia R, Cottle L, Chau G, Adeyeye A, Rinehart AR, McCauley M, Eron JS, Cohen MS, Landovitz RJ, Hendrix CW, Bumpus NN. PMID: 33615175.
      View in: PubMed   Mentions:
    2. Assessing the Role of Long-Acting Cabotegravir Preexposure Prophylaxis of Human Immunodeficiency Virus: Opportunities and Aspirations. J Infect Dis. 2021 Jan 04; 223(1):1-3. Cohen MS, Landovitz RJ. PMID: 32882042.
      View in: PubMed   Mentions:    Fields:    
    3. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. Ann Intern Med. 2020 Dec 08. Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, Kottkamp A, Neuzil KM, Laufer MK, Deming M, Paasche-Orlow MK, Kissinger PJ, Luk A, Paolino K, Landovitz RJ, Hoffman R, Schaafsma TT, Krows ML, Thomas KK, Morrison S, Haugen HS, Kidoguchi L, Wener M, Greninger AL, Huang ML, Jerome KR, Wald A, Celum C, Chu HY, Baeten JM. PMID: 33284679.
      View in: PubMed   Mentions:    Fields:    
    4. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2020 10 27; 324(16):1651-1669. PMID: 33052386.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    5. Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077. J Acquir Immune Defic Syndr. 2020 Sep 01; 85(1):93-97. Blair CS, Li S, Chau G, Cottle L, Richardson P, Marzinke MA, Eshleman SH, Adeyeye A, Rinehart AR, Margolis D, McCauley M, Hendrix CW, Landovitz RJ. PMID: 32452972.
      View in: PubMed   Mentions: 1     Fields:    
    6. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. AIDS Behav. 2020 Sep; 24(9):2520-2531. Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, Liu A, Siegel M, Bertha M, Panchia R, Li S, Cottle L, Rinehart A, Margolis D, Jennings A, McCauley M, Landovitz RJ. PMID: 32052214.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    7. PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM. Open Forum Infect Dis. 2020 Aug; 7(8):ofaa329. Blair CS, Beymer MR, Kofron RM, Bolan RK, Jordan WC, Haubrich RH, Wohl AR, Landovitz RJ. PMID: 32851110.
      View in: PubMed   Mentions:
    8. Cost-effectiveness of frequent HIV screening among high-risk young men who have sex with men in the United States. Clin Infect Dis. 2020 Jul 30. Neilan AM, Bulteel AJB, Hosek SG, Foote JHA, Freedberg KA, Landovitz RJ, Walensky RP, Resch SC, Kazemian P, Paltiel AD, Weinstein MC, Wilson CM, Ciaranello AL. PMID: 32730625.
      View in: PubMed   Mentions:    Fields:    
    9. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. J Infect Dis. 2020 Jul 09; 222(Supplement_1):S63-S69. Neilan TG, Nguyen KL, Zaha VG, Chew KW, Morrison L, Ntusi NAB, Toribio M, Awadalla M, Drobni ZD, Nelson MD, Burdo TH, Van Schalkwyk M, Sax PE, Skiest DJ, Tashima K, Landovitz RJ, Daar E, Wurcel AG, Robbins GK, Bolan RK, Fitch KV, Currier JS, Bloomfield GS, Desvigne-Nickens P, Douglas PS, Hoffmann U, Grinspoon SK, Ribaudo H, Dawson R, Goetz MB, Jain MK, Warner A, Szczepaniak LS, Zanni MV. PMID: 32645158.
      View in: PubMed   Mentions:    Fields:    
    10. Collective Call to Action for HIV/AIDS Community-Based Collaborative Science in the Era of COVID-19. AIDS Behav. 2020 07; 24(7):2013-2016. Shoptaw S, Goodman-Meza D, Landovitz RJ. PMID: 32300993.
      View in: PubMed   Mentions: 5     Fields:    
    11. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020 07; 7(7):e472-e481. PMID: 32497491.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Donate now to prevent sexually transmitted infections later: incentivising testing of sexually transmitted infections. Lancet Infect Dis. 2020 08; 20(8):885-886. Beymer MR, Landovitz RJ. PMID: 32530427.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    13. Novel Antiretroviral Agents. Curr HIV/AIDS Rep. 2020 04; 17(2):118-124. Cambou MC, Landovitz RJ. PMID: 32052271.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    14. Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. Clin Infect Dis. 2020 02 03; 70(4):687-691. Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG, Mulligan K. PMID: 31179503.
      View in: PubMed   Mentions: 2     Fields:    
    15. Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077. Clin Infect Dis. 2020 01 02; 70(2):319-322. Landovitz RJ, Zangeneh SZ, Chau G, Grinsztejn B, Eron JJ, Dawood H, Magnus M, Liu AY, Panchia R, Hosseinipour MC, Kofron R, Margolis DA, Rinehart A, Adeyeye A, Burns D, McCauley M, Cohen MS, Currier JS. PMID: 31125395.
      View in: PubMed   Mentions: 3     Fields:    
    16. Long-acting injectable cabotegravir for the prevention of HIV infection. Curr Opin HIV AIDS. 2020 01; 15(1):19-26. Clement ME, Kofron R, Landovitz RJ. PMID: 31644481.
      View in: PubMed   Mentions: 2     Fields:    
    17. Factors associated with repeat rectal Neisseria gonorrhoeae and Chlamydia trachomatis screening following inconclusive nucleic acid amplification testing: A potential missed opportunity for screening. PLoS One. 2019; 14(12):e0226413. Blair CS, Garner OB, Pedone B, Elias S, Comulada WS, Landovitz RJ. PMID: 31830129.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    18. HIV Preexposure Prophylaxis-The Role of Primary Care Clinicians in Ending the HIV Epidemic. JAMA Intern Med. 2019 Nov 18. Khalili J, Landovitz RJ. PMID: 31738380.
      View in: PubMed   Mentions: 2     Fields:    
    19. Long term surgical outcomes for infective endocarditis in people who inject drugs: a systematic review and meta-analysis. BMC Infect Dis. 2019 Nov 08; 19(1):918. Goodman-Meza D, Weiss RE, Gamboa S, Gallegos A, Bui AAT, Goetz MB, Shoptaw S, Landovitz RJ. PMID: 31699053.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Initiation of antiretroviral therapy with integrase strand-transfer inhibitor-based regimens and reduction of the risk of horizontal transmission of HIV-1. EClinicalMedicine. 2019 Dec; 17:100195. Berenguer J, Parrondo J, Landovitz RJ. PMID: 31891133.
      View in: PubMed   Mentions:
    21. Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV. 2019 11; 6(11):e788-e799. Coelho LE, Torres TS, Veloso VG, Landovitz RJ, Grinsztejn B. PMID: 31558423.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    22. Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals. Curr HIV/AIDS Rep. 2019 08; 16(4):349-358. Beymer MR, Holloway IW, Pulsipher C, Landovitz RJ. PMID: 31222499.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    23. Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART. PLoS One. 2019; 14(7):e0219802. Berenguer J, Parrondo J, Landovitz RJ. PMID: 31323075.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    24. Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. AIDS Care. 2019 10; 31(10):1228-1233. Goodman-Meza D, Beymer MR, Kofron RM, Amico KR, Psaros C, Bushman LR, Anderson PL, Bolan R, Jordan WC, Rooney JF, Wohl AR, Landovitz RJ. PMID: 30894013.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    25. Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. Clin Infect Dis. 2019 03 05; 68(6):1044-1047. Gandhi M, Bacchetti P, Ofokotun I, Jin C, Ribaudo HJ, Haas DW, Sheth AN, Horng H, Phung N, Kuncze K, Okochi H, Landovitz RJ, Lennox J, Currier JS. PMID: 30184104.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    26. Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions. J Int AIDS Soc. 2019 03; 22(3):e25247. Amico KR, Ramirez C, Caplan MR, Montgomery BE, Stewart J, Hodder S, Swaminathan S, Wang J, Darden-Tabb NY, McCauley M, Mayer KH, Wilkin T, Landovitz RJ, Gulick R, Adimora AA. PMID: 30869200.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    27. Complex decisions: correlates of injectable contraceptive discontinuation following HIV-1 seroconversion in an HIV prevention trial. AIDS Care. 2019 06; 31(6):746-753. Caplan MR, Landovitz RJ, Palanee-Phillips T, Nair G, Mhlanga F, Balkus JE, Riddler SA, Gorbach PM. PMID: 30759997.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    28. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. AIDS. 2019 02 01; 33(2):237-246. McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, McCauley M, Farley J, Mayer KH, Anton P, Brand RM, Cranston RD, Gulick R. PMID: 30557160.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    29. No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. PLoS One. 2018; 13(12):e0206577. Kapadia SN, Wu C, Mayer KH, Wilkin TJ, Amico KR, Landovitz RJ, Andrade A, Chen YQ, Chege W, McCauley M, Gulick RM, Schackman BR. PMID: 30586364.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    30. Where Is the Opioid Use Epidemic in Mexico? A Cautionary Tale for Policymakers South of the US-Mexico Border. Am J Public Health. 2019 01; 109(1):73-82. Goodman-Meza D, Medina-Mora ME, Magis-Rodríguez C, Landovitz RJ, Shoptaw S, Werb D. PMID: 30495992.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    31. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 11; 15(11):e1002690. Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ. PMID: 30408115.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    32. Acceptability of Injectable and On-Demand Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in California. LGBT Health. 2018 Aug/Sep; 5(6):341-349. Beymer MR, Gildner JL, Holloway IW, Landovitz RJ. PMID: 30118399.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    33. Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir. Clin Infect Dis. 2018 08 16; 67(5):791-794. Fulcher JA, Du Y, Zhang TH, Sun R, Landovitz RJ. PMID: 29933437.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    34. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 07 24; 320(4):379-396. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. PMID: 30043070.
      View in: PubMed   Mentions: 115     Fields:    Translation:Humans
    35. Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. AIDS Res Hum Retroviruses. 2018 05; 34(5):421-429. Figueroa DB, Madeen EP, Tillotson J, Richardson P, Cottle L, McCauley M, Landovitz RJ, Andrade A, Hendrix CW, Mayer KH, Wilkin T, Gulick RM, Bumpus NN. PMID: 29455571.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    36. Does HIV pre-exposure prophylaxis use lead to a higher incidence of sexually transmitted infections? A case-crossover study of men who have sex with men in Los Angeles, California. Sex Transm Infect. 2018 09; 94(6):457-462. Beymer MR, DeVost MA, Weiss RE, Dierst-Davies R, Shover CL, Landovitz RJ, Beniasians C, Talan AJ, Flynn RP, Krysiak R, McLaughlin K, Bolan RK. PMID: 29487172.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    37. Sexually Transmitted Infection Testing of HIV-Positive Medicare and Medicaid Enrollees Falls Short of Guidelines. Sex Transm Dis. 2018 01; 45(1):8-13. PMID: 29240633.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    38. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. . 2017 12 15; 76(5):501-511. PMID: 28902074.
      View in: PubMed   Mentions:
    39. Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County. Int J STD AIDS. 2018 05; 29(6):557-562. Beymer MR, Kofron RM, Tseng CH, Bolan RK, Flynn RP, Sayles JM, Perez MJ, Jordan WC, Landovitz RJ. PMID: 29183270.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    40. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. JAMA Pediatr. 2017 11 01; 171(11):1063-1071. Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, Harris DR, Mulligan K, Zimet G, Mayer KH, Anderson P, Kiser JJ, Lally M, Brothers J, Bojan K, Rooney J, Wilson CM. PMID: 28873128.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    41. Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med. 2017 Sep 19; 167(6):384-393. Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Siegel M, Manabe YC, Frank I, Ho K, Santana J, Stekler JD, Swaminathan S, McCauley M, Hodder S, Mayer KH. PMID: 28828489.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    42. HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights. AIDS Res Hum Retroviruses. 2017 08; 33(8):749-759. PMID: 28649869.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    43. Differentiating Nonoccupational Postexposure Prophylaxis Seroconverters and Non-Seroconverters in a Community-Based Clinic in Los Angeles, California. Open Forum Infect Dis. 2017; 4(2):ofx061. PMID: 28596981.
      View in: PubMed   Mentions:
    44. Serious concerns regarding a meta-analysis of preexposure prophylaxis use and STI acquisition. AIDS. 2017 03 13; 31(5):739-740. PMID: 28225452.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    45. Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). J Infect Dis. 2017 Jan 15; 215(2):238-246. PMID: 27811319.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    46. An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. . 2017 01 01; 74(1):21-29. PMID: 27632233.
      View in: PubMed   Mentions:
    47. Antiretroviral Therapy: Racial Disparities among Publicly Insured Californians with HIV. J Health Care Poor Underserved. 2017; 28(1):406-429. PMID: 28239010.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    48. HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav. 2016 12; 20(12):2983-2995. PMID: 26979419.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    49. Contingent Vs. Non-Contingent Rewards: Time-Based Intervention Response Patterns Among Stimulant-Using Men Who Have Sex With Men. J Subst Abuse Treat. 2017 01; 72:19-24. PMID: 27938777.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    50. Quality of Care for HIV/AIDS and for Primary Prevention by HIV Specialists and Nonspecialists. AIDS Patient Care STDS. 2016 09; 30(9):395-408. PMID: 27610461.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsPHPublic Health
    51. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12; 316(2):191-210. PMID: 27404187.
      View in: PubMed   Mentions: 149     Fields:    Translation:HumansCellsPHPublic Health
    52. Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy. AIDS. 2016 06 19; 30(10):1573-82. PMID: 26919735.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    53. Individual-Level, Partnership-Level, and Sexual Event-Level Predictors of Condom Use During Receptive Anal Intercourse Among HIV-Negative Men Who Have Sex with Men in Los Angeles. AIDS Behav. 2016 06; 20(6):1315-26. PMID: 26471884.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    54. Optimizing Delivery of Preexposure Prophylaxis--The Next Frontier. JAMA Intern Med. 2016 Jan; 176(1):85-6. PMID: 26571121.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    55. The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr Opin HIV AIDS. 2016 Jan; 11(1):122-8. PMID: 26633643.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansPHPublic Health
    56. Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way? J Infect Dis. 2016 May 15; 213(10):1519-20. PMID: 26681779.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    57. Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis. 2015 Sep; 2(3):ofv085. PMID: 26180834.
      View in: PubMed   Mentions:
    58. Benefits of PrEP as an Adjunctive Method of HIV Prevention During Attempted Conception Between HIV-uninfected Women and HIV-infected Male Partners. J Infect Dis. 2015 Nov 15; 212(10):1534-43. PMID: 26092856.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    59. Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation. Top Antivir Med. 2015 May-Jun; 23(2):85-90. PMID: 26200708.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    60. Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. Ann Intern Med. 2015 Mar 17; 162(6):461-2. PMID: 25775334.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    61. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015 06 15; 60(12):1842-51. PMID: 25767256.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    62. Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles. Int J STD AIDS. 2015 Dec; 26(14):1040-8. PMID: 25638214.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    63. Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men. Open Forum Infect Dis. 2015 Jan; 2(1):ofu114. PMID: 25884003.
      View in: PubMed   Mentions:
    64. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 07; 161(7):461-71. PMID: 25285539.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCellsCTClinical Trials
    65. Online Social Networking, Sexual Risk and Protective Behaviors: Considerations for Clinicians and Researchers. Curr Addict Rep. 2014 Sep; 1(3):220-228. PMID: 25642408.
      View in: PubMed   Mentions:
    66. Uptake and repeat use of postexposure prophylaxis in a community-based clinic in Los Angeles, California. AIDS Res Hum Retroviruses. 2014 Sep; 30(9):848-55. PMID: 24970113.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    67. Moving HIV PrEP from research into practice. Lancet Infect Dis. 2014 Sep; 14(9):781-3. PMID: 25065858.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    68. Commercial lubricant use among HIV-negative men who have sex with men in Los Angeles: implications for the development of rectal microbicides for HIV prevention. AIDS Care. 2014; 26(12):1609-18. PMID: 25022198.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    69. Sexual risk trajectories among MSM in the United States: implications for pre-exposure prophylaxis delivery. . 2014 Apr 15; 65(5):579-86. PMID: 24378726.
      View in: PubMed   Mentions:
    70. Epidemiology, sexual risk behavior, and HIV prevention practices of men who have sex with men using GRINDR in Los Angeles, California. J Urban Health. 2013 Aug; 90(4):729-39. PMID: 22983721.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    71. Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies. AIDS. 2013 Apr 24; 27(7):1119-28. PMID: 23262497.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    72. High-risk Sexual Behavior is Associated with Post-Exposure Prophylaxis Non-adherence among Men who have Sex with Men Enrolled in a Combination Prevention Intervention. J Sex Transm Dis. 2013; 2013:210403. PMID: 24527254.
      View in: PubMed   Mentions:
    73. A novel combination HIV prevention strategy: post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men. AIDS Patient Care STDS. 2012 Jun; 26(6):320-8. PMID: 22680280.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    74. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS. 2012 Feb; 26(2):87-94. PMID: 22149764.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansPHPublic Health
    75. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011 Jun; 8(2):94-103. Kelesidis T, Landovitz RJ. PMID: 21465112.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    76. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care. 2011 Sep; 23(9):1136-45. Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. PMID: 21476147.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    77. Aching for a diagnosis. J Hosp Med. 2010 Jan; 5(1):55-9. Afsarmanesh N, Nayeb-Hashemi H, Landovitz R. PMID: 20063393.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med. 2009 Oct 29; 361(18):1768-75. Landovitz RJ, Currier JS. PMID: 19864675.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic Health
    79. Occupational and nonoccupational postexposure prophylaxis for HIV in 2009. Top HIV Med. 2009 Jul-Aug; 17(3):104-8. Landovitz RJ. PMID: 19675368.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsPHPublic Health
    80. Availability of HIV postexposure prophylaxis services in Los Angeles County. Clin Infect Dis. 2009 Jun 01; 48(11):1624-7. Landovitz RJ, Combs KB, Currier JS. PMID: 19400685.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    81. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis. 2008 Oct 15; 198(8):1113-22. Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, Greaves W, Fätkenheuer G. PMID: 18783318.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCellsCTClinical Trials
    82. Updated guideline for occupational postexposure prophylaxis for HIV. AIDS Clin Care. 2008 Feb; 20(2):15. Landovitz RJ. PMID: 18399011.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    83. Recent efforts in biomedical prevention of HIV. Top HIV Med. 2007 Jun-Jul; 15(3):99-103. Landovitz RJ. PMID: 17598929.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    Raphael's Networks
    Concepts (266)
    Derived automatically from this person's publications.
    Co-Authors (27)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department